Published in Medical Letter on the CDC and FDA, September 17th, 2006
Revenue for the second quarter of 2006 was approximately $0.1 million, compared to $1.4 million in the second quarter of 2005. However, revenue was $1.5 million for the six months ended 2006 compared to $1.5 million for the six months ended 2005. The revenue was earned from two grants, a National Institute of Allergy and Infectious Diseases (NIAID) grant awarded in September 2004 for $5.2 million for RiVax, which was increased to $6.4 million in May 2005 for a renegotiated F&A rate which may be used for overhead expenditures, and for a September...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA